T. Rowe Price Investment Management Inc. Makes New Investment in Karyopharm Therapeutics Inc. $KPTI

Key Points

• T. Rowe Price Investment Management Inc. acquired 139,646 shares of Karyopharm Therapeutics, representing about 1.63% of the company's stock, valued at approximately $523,000.
• Karyopharm Therapeutics' stock performance has been volatile, with a 12-month range between $3.51 and $16.95, and a current price of $6.31.
• Research analysts have expressed mixed sentiments, with ratings varying from "buy" to "sell" and a consensus target price of $34.00.

T. Rowe Price Investment Management Inc. purchased a new stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 139,646 shares of the company's stock, valued at approximately $523,000. T. Rowe Price Investment Management Inc. owned 1.63% of Karyopharm Therapeutics at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of KPTI. Geode Capital Management LLC grew its position in Karyopharm Therapeutics by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company's stock valued at $942,000 after acquiring an additional 36,922 shares during the period. Marshall Wace LLP grew its holdings in shares of Karyopharm Therapeutics by 15.3% during the fourth quarter. Marshall Wace LLP now owns 2,401,413 shares of the company's stock worth $1,633,000 after purchasing an additional 319,187 shares during the last quarter. TD Waterhouse Canada Inc. bought a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth $32,000. Adage Capital Partners GP L.L.C. grew its holdings in shares of Karyopharm Therapeutics by 46.3% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company's stock worth $4,274,000 after purchasing an additional 2,000,000 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Karyopharm Therapeutics by 23.5% during the fourth quarter. Northern Trust Corp now owns 283,729 shares of the company's stock worth $192,000 after purchasing an additional 54,061 shares during the last quarter. 66.44% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics Stock Down 7.4%

KPTI stock traded down $0.57 during midday trading on Friday, reaching $7.11. The stock had a trading volume of 132,469 shares, compared to its average volume of 214,607. The business has a fifty day simple moving average of $4.81 and a two-hundred day simple moving average of $5.40. The firm has a market cap of $61.65 million, a price-to-earnings ratio of -0.49 and a beta of 0.28. Karyopharm Therapeutics Inc. has a twelve month low of $3.51 and a twelve month high of $16.95.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($4.32) EPS for the quarter, missing analysts' consensus estimates of ($3.80) by ($0.52). The company had revenue of $37.93 million during the quarter, compared to analysts' expectations of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. On average, equities analysts predict that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on KPTI shares. Royal Bank Of Canada decreased their target price on Karyopharm Therapeutics from $34.00 to $33.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. HC Wainwright cut Karyopharm Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, July 16th. Robert W. Baird decreased their target price on Karyopharm Therapeutics from $42.00 to $25.00 and set an "outperform" rating on the stock in a report on Tuesday, August 12th. Barclays upped their price target on Karyopharm Therapeutics from $5.00 to $10.00 and gave the company an "overweight" rating in a research note on Tuesday, May 13th. Finally, Wall Street Zen lowered Karyopharm Therapeutics from a "hold" rating to a "sell" rating in a research report on Wednesday, May 14th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Karyopharm Therapeutics has an average rating of "Moderate Buy" and an average price target of $34.00.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).